PROTACs (Proteolysis-Targeting Chimeras) and molecular glue degraders represent a transformative therapeutic modality for neurodegenerative diseases. Unlike traditional small-molecule inhibitors that require continuous occupancy to block protein function, PROTACs leverage the cell's own ubiquitin-proteasome system to selectively eliminate disease-causing proteins[1]. This catalytic mechanism offers potential advantages including lower dosing, enhanced efficacy against proteins previously considered "undruggable," and the ability to target pathological protein aggregates that drive neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[2].
This deep-dive focuses on the application of PROTACs and molecular glue degraders to three major CNS protein targets: tau, alpha-synuclein, and TDP-43. Each target presents unique challenges and opportunities for degradation-based therapeutics.
PROTACs are heterobifunctional molecules composed of three essential elements[1:1]:
When a PROTAC molecule binds simultaneously to the target protein and an E3 ligase, it brings them into close proximity. This enables the E3 ligase to ubiquitinate the target protein, marking it for degradation by the proteasome. Unlike traditional inhibitors, PROTACs act catalytically — one PROTAC molecule can induce the degradation of multiple target protein molecules[3].
Molecular glue degraders are small molecules that function through a similar principle but with a simpler structure. Rather than having two distinct binding domains, molecular glues act as molecular "adhesives" that stabilize interactions between a target protein and an E3 ligase. Examples include immunomodulatory imide drugs (IMiDs) such as lenalidomide and pomalidomide, which induce degradation of IKZF1/3 transcription factors[4]. Recent advances have identified molecular glues targeting tau pathology and TDP-43 aggregates[5].
Tau protein aggregation into neurofibrillary tangles is a hallmark of Alzheimer's disease and several other tauopathies, including progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD)[6]. PROTACs designed to degrade tau have shown promise in preclinical models.
Research has demonstrated that tau PROTACs can effectively reduce tau levels in cellular and animal models. A notable study developed a tau PROTAC using the tau-binding compound K18 and a VHL E3 ligase recruiter, demonstrating significant tau degradation in HEK293 cells expressing tau and in a Caenorhabditis elegans tau model[7]. Another approach utilized CRBN-based tau PROTACs with enhanced blood-brain barrier (BBB) penetration properties[8].
Key findings from tau PROTAC research:
Molecular glue degraders offer an alternative approach to tau degradation. These compounds can induce the degradation of specific tau isoforms or mutant forms associated with familial Alzheimer's disease[5:1].
Alpha-synuclein aggregation is central to Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy (MSA)[9]. PROTAC-based approaches targeting alpha-synuclein have shown preclinical promise.
Several research groups have developed PROTACs targeting alpha-synuclein. A notable approach utilized the small molecule "Synucleozid" as the target-binding ligand, conjugated to VHL or CRBN E3 ligase recruiters. These PROTACs demonstrated effective alpha-synuclein degradation in cellular models, including neurons derived from Parkinson's disease patient iPSCs[10].
Key considerations for alpha-synuclein PROTACs:
| Target | Model System | Key Findings | References |
|---|---|---|---|
| Tau | HEK293 tau cells | >90% degradation with CRBN-based PROTACs | [7:1][8:1] |
| Tau | C. elegans | Improved motor function, reduced tau pathology | [7:2] |
| α-Syn | iPSC-derived neurons | Reduced aggregates, preserved neurite morphology | [10:1] |
| α-Syn | Mouse models | Decreased Lewy body-like pathology | [11] |
TDP-43 (TAR DNA-binding protein 43) pathology is a hallmark of amyotrophic lateral sclerosis (ALS) and approximately 50% of Alzheimer's disease cases[12]. TDP-43 forms cytoplasmic aggregates in affected neurons, and its nuclear loss-of-function contributes to disease pathogenesis.
PROTACs targeting TDP-43 face the challenge that TDP-43 is an essential nuclear protein with normal physiological functions. Therefore, therapeutic approaches must aim to degrade pathological TDP-43 aggregates while preserving normal nuclear TDP-43 function[13].
Molecular glue approaches have shown promise for TDP-43. Research has identified compounds that selectively degrade TDP-43 aggregates without affecting physiological TDP-43 levels in cellular models[5:2]. These aggregate-selective degraders represent a promising strategy to avoid the toxicity associated with complete TDP-43 loss.
The blood-brain barrier (BBB) represents the foremost challenge for CNS-acting PROTACs. The BBB restricts the passage of large molecules and many small molecules, requiring careful optimization of PROTAC properties[14].
PROTACs often require sustained exposure to maintain target degradation. The catalytic nature of PROTACs can allow for intermittent dosing, but achieving adequate brain concentrations remains challenging[14:1].
As of 2024, no PROTACs or molecular glues have been approved for neurodegenerative disease indications. However, the field is rapidly advancing:
| Modality | Advantages | Challenges |
|---|---|---|
| PROTACs | Catalytic, undruggable targets | BBB penetration, off-target effects |
| ASOs | Highly selective | Invasive delivery, peripheral effects |
| Antibodies | High specificity | BBB penetration, cost |
| Small molecules | Oral delivery possible | Limited target scope |
Neklesa TK, Crews CM. Greased wheels: the development of PROTACs. Nature Chemical Biology. 2022. ↩︎ ↩︎
Guarnieri M, Peviani M. Targeted protein degradation for neurodegenerative diseases. Nature Reviews Drug Discovery. 2023. ↩︎
Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery. 2022. ↩︎
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010. ↩︎
Liu G, Huang R, Yu M, et al. Molecular glue induces selective degradation of pathological tau aggregates. Cell Reports. 2024. ↩︎ ↩︎ ↩︎
Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathologica. 2017. ↩︎
Chu TT, Gao N, Chen X, et al. Development of tau PROTACs for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry. 2023. ↩︎ ↩︎ ↩︎
Kargbo RB. PROTAC treatment for tau protein in Alzheimer's disease. ACS Medicinal Chemistry Letters. 2023. ↩︎ ↩︎
Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997. ↩︎
Thanawala S, Bhandari D, Kour S, et al. Development of alpha-synuclein PROTACs as a therapeutic strategy for Parkinson's disease. Journal of Parkinson's Disease. 2024. ↩︎ ↩︎
Zellefrow C, Karpinar D, Driessen W, et al. PROTAC-mediated alpha-synuclein degradation in mouse models of Parkinson's disease. Movement Disorders. 2023. ↩︎
Neumann M, Sampathu DM, Kwong LK, et al. TDP-43 positive frontotemporal lobar degeneration. Science. 2006. ↩︎
Riku Y, Atsuta N, Yoshida M, et al. Differential motor and UI morphology in TDP-43 proteinopathy. Acta Neuropathologica. 2022. ↩︎
Poongadan R, Beak D, Kwon Y, et al. Blood-brain barrier challenges for PROTAC degraders. Neurobiology of Disease. 2024. ↩︎ ↩︎
Xie Y, Chen X, Wu Q, et al. Engineering BBB-crossing PROTACs using receptor-mediated transcytosis. Journal of Controlled Release. 2024. ↩︎